OTCMKTS:CUBTD Curative Biotechnology (CUBTD) Stock Price, News & Analysis $1.10 0.00 (0.00%) As of 10/7/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Curative Biotechnology Stock (OTCMKTS:CUBTD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Curative Biotechnology alerts:Sign Up Key Stats Today's Range$1.10▼$1.1050-Day Range$1.10▼$1.1052-Week Range$0.03▼$2.24VolumeN/AAverage Volume2,679 shsMarket Capitalization$7.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Curative Biotechnology, Inc. is a development-stage biotechnology company focused on discovering and advancing therapies for serious medical conditions. Its stated areas of interest include rare diseases, cancer and infectious diseases. The company’s activities center on pharmaceutical research and development, including the evaluation of potential drug candidates and the pursuit of partnerships or other arrangements that may support clinical development and commercialization. As an early-stage biotechnology business, Curative Biotechnology’s programs remain subject to research, regulatory and clinical-development risks. Publicly available information about the company’s specific products, clinical programs, geographic operations and leadership is limited. Accordingly, Curative Biotechnology is best described as an emerging biotechnology developer rather than an established commercial pharmaceutical company.AI Generated. May Contain Errors. Read More Receive CUBTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curative Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUBTD Stock News HeadlinesCurative Biotechnology, Inc. Issues Letter to ShareholdersSeptember 11, 2026 | markets.businessinsider.comCurative Biotechnology Inc.July 24, 2026 | marketwatch.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 9 at 1:00 AM | Investors Alley (Ad)Curative Biotechnology Announces U.S. Patent Allowance Strengthening Core Ophthalmology PlatformJuly 17, 2026 | markets.businessinsider.comCurative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research AgreementMay 7, 2026 | tmcnet.comCurative Biotechnology, Inc.: Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic TherapyApril 21, 2026 | finanznachrichten.deCurative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic TherapyApril 16, 2026 | markets.businessinsider.comCurative Biotechnology, Inc.?: Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB UplistingMarch 24, 2026 | finanznachrichten.deSee More Headlines CUBTD Stock Analysis - Frequently Asked Questions How have CUBTD shares performed this year? Curative Biotechnology's stock was trading at $0.81 at the beginning of 2026. Since then, CUBTD shares have increased by 35.8% and is now trading at $1.10. When did Curative Biotechnology's stock split? Curative Biotechnology shares reverse split on Monday, March 30th 2026.The 1-150 reverse split was announced on Monday, March 30th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 30th 2026. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Curative Biotechnology? Shares of CUBTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Curative Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curative Biotechnology investors own include Ayala Pharmaceuticals (ADXS), Invesco S&P Global Water Index ETF (CGW), Surge Battery Metals (NILIF), Pressure BioSciences (PBIO) and ACRO (TACI). Company Calendar Today10/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:CUBTD Previous SymbolOTCMKTS:CTYX CIK1400271 Webcurativebiotech.com Phone(561) 418-7725Fax866-900-1002Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares6,820,000Free FloatN/AMarket Cap$7.50 million OptionableNot Optionable Beta1.31 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:CUBTD) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curative Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curative Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
